Idiopathic Pulmonary Fibrosis
Conditions
Brief summary
To evaluate the efficacy and safety of intravenous SHR-1906 in the treatment of idiopathic pulmonary fibrosis. The study is divided into four stages: screening period, baseline period, treatment period and safe follow-up period. It is planned that 108 patients will be randomly assigned to the following three treatment groups for treatment
Interventions
DRUGSHR-1906
Intravenous injection
DRUGPlacebo
Placebo，Intravenous injection
Sponsors
Guangdong Hengrui Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Comparison of SHR-1906 injection and placebo
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age 40 to 80, inclusive, at the time of screening； 2. IPF diagnosed according to ATS/ERS/JRS/ALAT guidelines (2022) (HRCT diagnosis UIP type/possible UIP type (standard HRCT confirmed by central review in recent 3 months) with or without pathological UIP type/possible UIP type (pathology refers to frozen lung biopsy or surgical/thoracoscopic lung biopsy)； 3. 90% ≥ FVCpp ≥ 45% during screening period and the first day; 4. The percent of predicted DLCO value (corrected by Hb value) at screening is ≥ 30% and ≤ 90%; 5. Before the screening period, pirfenidone or nidanib with stable dose ≥ 8 weeks (pirfenidone ≥ 1200 mg/denidanib ≥ 200 mg/d) can continue to maintain treatment with stable dose during the study period; Or at least 4 weeks before the screening period, pirfenidone or nidanib was not used (pirfenidone or nidanib was refused due to intolerance or various factors) ；
Exclusion criteria
1. Evidence of any of the following significant obstructive pulmonary disease: (1) The ratio of forced expiratory volume/forced vital capacity (FEV1/FVC) at the first second is \< 0.70 (after using bronchodilator) or (2) HRCT shows that emphysema is greater than fibrosis; 2. Interstitial lung diseases (ILD) other than IPF include but are not limited to: any other type of idiopathic interstitial pneumonia; Lung diseases related to contact with fibroblasts or other environmental toxins or drugs; Other types of occupational lung diseases; Granulomatous lung disease; Pulmonary vascular disease; Systemic diseases include vasculitis infectious diseases (i.e. Tuberculosis) and connective tissue diseases If the diagnosis is unclear, serological examination and/or multidisciplinary expert group review should be conducted to confirm IPF or other types of ILD diagnosis; 3. A history of other types of respiratory diseases, including respiratory tract, lung parenchyma, pleural cavity, mediastinum, diaphragm or chest wall diseases or disorders, such as acute respiratory infection, active tuberculosis, etc., which researchers believe will affect the primary endpoint of the study or otherwise affect the participation of subjects in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in FVC% (Percent of Predicted FVC value) to week 24 | Baseline, Week 24 |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in FVC% (Percent of Predicted FVC value) to Week 4, 8, 12, 16, 20 | Baseline, Week 4, 8, 12, 16, 20 |
| Change from Baseline in Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) to Week 12 and Week 24 | Baseline, Week 12 and Week 24 |
| Change from Baseline in St. George's Respiratory Questionnaire (SGRQ) Scores to Week 12 and Week 24 | Baseline, Week 12 and Week 24] |
| Number of Praticipants with an Acute Exacerbation of IPF | Start of Treatment to end of study (approximately 28 weeks) |
| Change from Baseline in FVC (L) to Week 4, 8, 12, 16, 20, 24 | Baseline, Week 4, 8, 12, 16, 20, 24 |
| Adverse events | Start of Treatment to end of study (approximately 28 weeks) |
| Serum concentration of SHR-1906 | Start of Treatment to end of study (approximately 28 weeks) |
| Proportion of anti-SHR-1906 antibody (ADA) formed during the study from baseline | Start of Treatment to end of study (approximately 28 weeks) |
| All-cause mortality | Start of Treatment to end of study (approximately 28 weeks) |
Countries
China
Outcome results
None listed